ライフサイエンスコーパス: blood eosinophil

1 tions of type 2 biomarkers (eg, periostin or blood eosinophils).

2 reduced levels of allergen-specific IgE and blood eosinophils.

3 phosphorylation after IL-5 priming of human blood eosinophils.

4 se, and adherence to fibronectin relative to blood eosinophils.

5 at CD127 is present in highly purified human blood eosinophils.

6 ukemia cell line EoL-1 as well as peripheral blood eosinophils.

7 for efficient isolation of human peripheral blood eosinophils.

8 ssion and role of CD30 in apoptosis of human blood eosinophils.

9 ntly expressed in airway eosinophils than in blood eosinophils.

10 LTC4) synthesis in isolated human peripheral blood eosinophils.

11 phosphatidylcholine in fMLP-stimulated human blood eosinophils.

12 mRNA were not increased in BAL compared with blood eosinophils.

13 nd decreased IL-5 and eotaxin receptors than blood eosinophils.

14 strong chemotactic activity for normal human blood eosinophils.

15 acerbations did not increase with increasing blood eosinophils.

16 ren based on the molecular patterns of their blood eosinophils.

17 These subjects also displayed higher blood eosinophils (0.65 vs 0.39, P = 0.021), higher Frac

18 Blood eosinophils (10(9) x l(-1)), bronchial inflammatio

19 Baseline: IgE, 307 +/- 133 Kmu; total blood eosinophils, 296 +/- 149 cells/muL; body mass inde

20 ving high-dosage ICS plus LABA with baseline blood eosinophils 300 cells per muL or greater (intentio

21 tients with severe, uncontrolled asthma with blood eosinophils 300 cells per muL or greater.

22 Baseline: IgE, 332 +/- 243 Kmu; total blood eosinophils, 304 +/- 266 cells/muL; body mass inde

23 Among all participants with COPD, blood eosinophils above versus below 0.34 x 10(9) cells

24 In static assays, unactivated purified human blood eosinophils adhered similarly to recombinant solub

25 Blood eosinophils adhering to adsorbed periostin were im

26 d ERK1/2 phosphorylation observed in primary blood eosinophils after priming with IL-3/GM-CSF, and sm

27 When compared with blood eosinophils, airway eosinophils exhibited greater

28 Blood eosinophils alone were not a reliable biomarker fo

29 The increase in blood eosinophil and basophil counts during high-dose as

30 Blood eosinophil and basophil levels increased and urina

31 Blood eosinophil and C-reactive protein levels were also

32 icant associations, Feno levels, IgE levels, blood eosinophil and neutrophil counts, FEV1 percent pre

33 ssessed its enzymatic activity in peripheral blood eosinophils and an eosinophil myelocyte cell line

34 or associations between activation states of blood eosinophils and features of asthma are reviewed he

35 of control, and markers of TH2 inflammation (blood eosinophils and fraction of exhaled nitric oxide).

36 cs with mepolizumab significantly attenuated blood eosinophils and increased EoP numbers consistent w

37 ilization were conducted in human peripheral blood eosinophils and mouse bone marrow-derived eosinoph

38 erum IgG1 levels and inhibited elevations in blood eosinophils and mucosal mast cells at day 14 after

39 thma) parameters of inflammation (peripheral blood eosinophils and neutrophils) and markers of hemost

40 29 epitope of activated beta(1) integrins on blood eosinophils and of alpha(M), beta(2), and the mAb2

41 receptor mRNA and protein in most peripheral blood eosinophils and pregranulocytic CD34+ cells, and i

42 ponsiveness and concentrations of peripheral blood eosinophils and sputum eosinophils were also asses

43 in vitro to induce chemotaxis of peripheral blood eosinophils and to induce histamine release from I

44 ers, in situ CD4+ T cell expansion, elevated blood eosinophils, and increased intestinal mucosal mast

45 stitutively active in freshly isolated human blood eosinophils, and inhibition of Notch signaling or

46 uated aeroallergen sensitization, peripheral blood eosinophils, and serum periostin as potential biom

47 ing treatment effects in relation to FE(NO), blood eosinophils, and serum periostin at baseline.

48 93.8%), and 534 (62.8%) patients for FE(NO), blood eosinophils, and serum periostin, respectively.

49 Elevated numbers of blood eosinophils are a risk factor for asthma exacerbat

50 Whether high blood eosinophils are associated with chronic obstructiv

51 greater exacerbation frequency, and whether blood eosinophils are predictive of sputum eosinophils.

52 Short-lived peripheral blood eosinophils are recruited to the lungs of asthmati

53 life aeroallergen sensitization and elevated blood eosinophils are robust predictors of asthma develo

54 his review was to summarize the evidence for blood eosinophils as a predictive biomarker for corticos

55 We prospectively investigated the value of blood eosinophils as a predictor of responsiveness to an

56 opoietin receptor was observed on peripheral blood eosinophils as well as on tissue infiltrating eosi

57 We recorded blood eosinophils at baseline and future COPD exacerbati

58 rom this construct transduced isolated human blood eosinophils at more than 95% efficiency.

59 ol, lung function, bronchial responsiveness, blood eosinophils, atopy and treatment level were assess

60 sinophils from the circulation requires that blood eosinophils become activated, leading to their arr

61 ction of exhaled nitric oxide (Feno) values, blood eosinophil (bEOS) counts, serum CCL26 expression,

62 Before anti-IL-5, surface densities of blood eosinophil beta(2) , alpha(M) and alpha(L) integri

63 In the SARP-3 multivariable model, blood eosinophils, body mass index, and bronchodilator r

64 76/88 (86%) had normal blood eosinophils, but of these, 84% had airway eosinoph

65 othelial cells, and is induced in peripheral blood eosinophils by interleukin-3.

66 In addition, allergic sensitization and blood eosinophils can be used to select medications for

67 Therefore, normal peripheral blood eosinophils can transcribe and synthesize several

68 The decrease of CRTH2 on blood eosinophils clearly correlated with disease activi

69 benralizumab-treated patients with baseline blood eosinophil concentrations of 200 cells per muL or

70 We also analysed whether blood eosinophil concentrations reliably predicted sputu

71 marker-positive and -negative exacerbations (blood eosinophil count > and </= 2%, respectively).

72 hilic phenotype were stratified according to blood eosinophil count (>/=150 per cubic millimeter at s

73 % and >/=3%, and <5% and >/=5%) and absolute blood eosinophil count (<150 cells/mul, 150 to <300 cell

74 ith pneumonia events, stratified by baseline blood eosinophil count (<2% vs >/=2% of blood leucocytes

75 FeNO, airway responsiveness, blood eosinophil count (B-Eos) and IgE sensitization to

76 Fraction of exhaled nitric oxide (Feno) and blood eosinophil count (B-Eos) values, markers of local

77 st total serum IgE level (median, 733 kU/L), blood eosinophil count (median, 400 cells/mm(3)), and al

78 = -0.42, p < 0.001) and with the peripheral blood eosinophil count (r = 0.34, p < 0.001) in the grou

79 ecrease from baseline in the main peripheral blood eosinophil count 24 h after the fourth injection c

80 randomly allocated them (1:1; stratified by blood eosinophil count [<300 cells per muL vs >/=300 cel

81 shown a close relationship between baseline blood eosinophil count and clinical efficacy of mepolizu

82 We investigated the relation between blood eosinophil count and prospective annual asthma out

83 The most well established of these are the blood eosinophil count and serum periostin, both of whic

84 gressively with nine ascending categories of blood eosinophil count as compared with a reference cate

85 lonal antibody against IL-5 lowered the mean blood eosinophil count at day 29 from 0.25x10(9)/L (95%

86 here was a comparable decrease in peripheral blood eosinophil count beginning 5 h after challenge, wh

87 matching placebo was given according to the blood eosinophil count biomarker.

88 Blood eosinophil count could potentially be used to stra

89 Blood eosinophil count is a promising biomarker of respo

90 The peripheral blood eosinophil count is a promising biomarker to direc

91 We investigated whether blood eosinophil count is a useful biomarker of the long

92 eroid treatment for COPD have shown that the blood eosinophil count is associated with the risk of CO

93 Blood eosinophil count mediated 29% of the life-course-p

94 than 2% and it was therefore postulated that blood eosinophil count might also have an effect on the

95 0.48, 0.39-0.58) in patients with a baseline blood eosinophil count of at least 150 cells per muL to

96 In METREO, all patients had a blood eosinophil count of at least 150 per cubic millime

97 persistent, moderate-to-severe asthma and a blood eosinophil count of at least 300 cells per microli

98 , to maintain a stable clinical status and a blood eosinophil count of less than 1000 per microliter.

99 A blood eosinophil count of less than 600 per microliter f

100 The mean blood eosinophil count was 200/muL (SD, 144/muL).

101 assessed on the basis of total IgE level and blood eosinophil count) and serum periostin level.

102 pred of 75.1%, median values of 300/mm(3) of blood eosinophil count, 323 kU/L of serum total IgE, and

103 The combination of blood eosinophil count, fractional exhaled nitric oxide,

104 neous lesions, treatment of rash, peripheral blood eosinophil count, tumor response, and skin histolo

105 a prespecified subgroup analysis by baseline blood eosinophil count.

106 xacerbations was independent of the baseline blood eosinophil count.

107 blood counts, and so were stratified by mean blood eosinophil count: 1262 patients with low (<200 cel

108 sly increased Feno levels (>/=20-25 ppb) and blood eosinophil counts (>/=0.3 x 10(9)/L) had a higher

109 re, <20) than subjects with singly increased blood eosinophil counts (40.5% vs 21.1%, P = .01).

110 il counts or singly increased Feno levels or blood eosinophil counts (85.7% vs 35.8% or 63.3% or 60%,

111 exhaled nitric oxide values (14.5 ppb), and blood eosinophil counts (96 cells/muL) than all other gr

112 Increases in blood eosinophil counts (EOS) beyond 0.06 x 10(9)/liter

113 hase were evaluated with respect to baseline blood eosinophil counts (eosinophils <300/muL [low] vs >

114 a (odds ratio, 32.6; P = 6.9 x 10(-7)), high blood eosinophil counts (odds ratio, 9.1; P = 2.6 x 10(-

115 gents caused similar decreases in peripheral blood eosinophil counts (P < 0.05 for each agent compare

116 ur-week UDCA treatment significantly reduced blood eosinophil counts (P <.0001) and serum MBP (P <.00

117 nts and subjects with normal Feno levels and blood eosinophil counts (P = .02) after adjusting for co

118 Increased peripheral blood eosinophil counts (patients with EG: 1.09 +/- 0.88

119 correlation found was between IgE levels and blood eosinophil counts (r = 0.33, P < .001); furthermor

120 Patients were stratified (2:1) by baseline blood eosinophil counts 300 cells per muL or greater and

121 re, a count-response relation exists between blood eosinophil counts and asthma-related outcomes.

122 ant association between sputum or peripheral blood eosinophil counts and body mass index.

123 To assess the relationship between baseline blood eosinophil counts and efficacy of mepolizumab we d

124 irin reactions correlated with reductions in blood eosinophil counts and lung function and increases

125 i-interleukin-5 monoclonal antibody, reduces blood eosinophil counts and may have value in the treatm

126 number of controller medications, and total blood eosinophil counts and negatively with the Asthma C

127 subjects with both increased Feno levels and blood eosinophil counts and subjects with normal Feno le

128 each on serum immunoglobulin E (IgE) levels, blood eosinophil counts and three on lung function as me

129 cationic protein in nasal washes, along with blood eosinophil counts and total and allergen-specific

130 sone); and pre-randomisation measurements of blood eosinophil counts and were of at least 24 weeks in

131 gion, screening periostin concentration, and blood eosinophil counts as covariates.

132 ults were observed in patients regardless of blood eosinophil counts at enrollment.

133 267 in the benralizumab 30 mg Q8W group had blood eosinophil counts at least 300 cells per muL and w

134 Blood eosinophil counts at screening were related to the

135 bations was found among patients with higher blood eosinophil counts at screening.

136 Blood eosinophil counts could add predictive value to Gl

137 asthma with recurrent exacerbations and high blood eosinophil counts despite use of inhaled corticost

138 measured at weeks 1 and 4 with monitoring of blood eosinophil counts for up to 16 weeks.

139 Patients with asthma and blood eosinophil counts greater than 400 cells per muL e

140 verall, 20 929 (16%) of 130 248 patients had blood eosinophil counts greater than 400 cells per muL.

141 eroids, 40 (3.8%) patients with less than 2% blood eosinophil counts had a pneumonia event versus 48

142 s a threshold, patients with COPD with lower blood eosinophil counts had more pneumonia events than d

143 in urinary eicosanoid metabolite levels and blood eosinophil counts in patients with AERD who tolera

144 ght to investigate increased Feno levels and blood eosinophil counts in relation to lung function, br

145 notyping with aeroallergen sensitization and blood eosinophil counts is useful for guiding treatment

146 vidence that patients with COPD and baseline blood eosinophil counts less than 2% have a poorer respo

147 Blood eosinophil counts might predict response to inhale

148 less than 2% and 6818 patients had baseline blood eosinophil counts of 2% or more.

149 ren with both aeroallergen sensitization and blood eosinophil counts of 300/muL or greater.

150 are odds of asthma control for patients with blood eosinophil counts of 400 cells per muL or less ver

151 AER among patients with baseline blood eosinophil counts of at least 0 cells per muL was

152 Patients were stratified 2:1 according to blood eosinophil counts of at least 300 cells per muL an

153 symptom score at week 48, for patients with blood eosinophil counts of at least 300 cells per muL.

154 in 1 s (FEV1 in L) in patients with baseline blood eosinophil counts of at least 300 eosinophils per

155 4043 patients had baseline blood eosinophil counts of less than 2% and 6818 patient

156 on of exhaled nitric oxide (Feno) levels and blood eosinophil counts offer additive information in re

157 No differences were documented in blood eosinophil counts or serum markers after eHF intak

158 evere BHR than having normal Feno levels and blood eosinophil counts or singly increased Feno levels

159 Having increased Feno levels and blood eosinophil counts related to a higher prevalence o

160 Blood eosinophil counts showed a weak but significant as

161 ificantly higher total IgE levels and higher blood eosinophil counts than those with the lower-risk g

162 Measurements of Feno levels and blood eosinophil counts were available in 406 subjects (

163 Blood eosinophil counts were increased in bilirubin-trea

164 lizumab in patients with asthma and elevated blood eosinophil counts who are inadequately controlled

165 ssess whether patients with COPD with higher blood eosinophil counts would be more likely to have exa

166 atients' survival nor to serum IgE levels or blood eosinophil counts, a finding suggesting that this

167 etermine the predictive value of IgE levels, blood eosinophil counts, and fraction of exhaled nitric

168 EV1, PC20, fraction of exhaled nitric oxide, blood eosinophil counts, and inhaled steroid treatment d

169 ) with questionnaire, spirometry, peripheral blood eosinophil counts, and testing for airway responsi

170 ic inflammation, including serum IgE levels, blood eosinophil counts, and tissue eosinophil counts.

171 levels, and FEV1 percent predicted, but not blood eosinophil counts, correctly predicted 69% of sput

172 Intraepithelial peak eosinophil and blood eosinophil counts, esophageal-related symptoms, se

173 We sought to determine whether blood eosinophil counts, Feno levels, and IgE levels acc

174 ociation with sputum eosinophil percentages, blood eosinophil counts, Feno levels, and total IgE leve

175 in patients with increased serum IgE levels, blood eosinophil counts, or both were also negative.

176 mab clinical development program showed that blood eosinophil counts, rather than sputum or tissue eo

177 Variables, such as blood eosinophil counts, total IgE levels, fraction of e

178 ures of gastric biopsy specimens, as well as blood eosinophil counts, were analyzed in patients with

179 ith severe, uncontrolled asthma and elevated blood eosinophil counts.

180 h life-course-persistent asthma had elevated blood eosinophil counts.

181 ho received placebo, independent of baseline blood eosinophil counts.

182 L) and 1237 with high (>/=200 cells per muL) blood eosinophil counts.

183 In patients with a baseline blood eosinophil cutoff of at least 300 cells per muL, e

184 artate protease(s) and that human peripheral blood eosinophils degranulate in response to the cell-fr

185 Blood eosinophils demonstrate circadian cycling, as desc

186 atient experienced an increase in peripheral blood eosinophils during the clinical course and receive

187 Human blood eosinophils exhibit a hyperactive phenotype in res

188 Human blood eosinophils exposed ex vivo to hematopoietic cytok

189 analysis, we previously observed that human blood eosinophils express mRNA for IL-7R alpha (CD127) a

190 We show for the first time that human blood eosinophils express Notch receptors and Notch liga

191 Human peripheral blood eosinophils express the ADO A3 receptor as indicat

192 respectively, of freshly isolated peripheral blood eosinophils for 72 h, compared with 20% +/- 8% sur

193 We evaluated mature peripheral blood eosinophils for their expression of the surface ty

194 ose of monoclonal antibody to IL-5 decreased blood eosinophils for up to 16 weeks and sputum eosinoph

195 kit was expressed on the purified peripheral blood eosinophils from 8 of 8 donors (4 nonatopic and 4

196 Blood eosinophils from children and adults with EoE, and

197 AML14.3D10 cell line and purified peripheral blood eosinophils from normal donors.

198 To address these issues, we studied blood eosinophils from patients with ragweed hay fever.

199 Human peripheral blood eosinophils generate superoxide (O2.-) in response

200 The high blood eosinophil group had slightly increased airway wal

201 significantly different between low and high blood eosinophil groups, but differences were less than

202 rker-high patients (periostin >/=50 ng/mL or blood eosinophils >/=300 cells per muL), analysed with a

203 y corticosteroid response and the biomarker 'blood eosinophils' has emerged as an attractive candidat

204 RATIONALE: Post hoc analyses suggest that blood eosinophils have potential as a predictive biomark

205 airway hyperresponsiveness, more airway and blood eosinophils, higher serum IgE, more subepithelial

206 monia event versus 48 (2.4%) with 2% or more blood eosinophils (HR 1.53; 95% CI 1.01-2.31).

207 suggest from these experiments that in human blood eosinophils, IL-5R alpha gene transcription and IL

208 AM-1 increased viability of human peripheral blood eosinophil in a dose- and time-dependant manner wh

209 ing in GM-CSF-primed transmigration of human blood eosinophils in vitro and in the airway accumulatio

210 IL-5 activates alpha(M) beta(2) integrin on blood eosinophils in vitro.

211 r Lyn before cytokine (IL-5/IL-3) priming of blood eosinophils inhibited the synergistic increase of

212 expressed on the surface of human peripheral blood eosinophils isolated from healthy individuals.

213 Blood eosinophil KIM-127 reactivity at the time of chall

214 th COPD in the general population, increased blood eosinophil levels above 0.34 x 10(9) cells per lit

215 aled a direct correlation between peripheral blood eosinophil levels and B cell numbers.

216 In patients with allergic asthma, baseline blood eosinophil levels and/or clinical markers of asthm

217 However, normal blood eosinophil levels did not exclude airway eosinophi

218 ts over salmeterol/fluticasone regardless of blood eosinophil levels in patients with COPD.

219 function, total serum immunoglobulin E, and blood eosinophil levels.

220 neously increased local (Feno) and systemic (blood eosinophil) markers of type 2 inflammation related

221 examined by flow cytometry using peripheral blood eosinophils, mast cell lines, and Siglec-8-transdu

222 try for age, asthma duration, lung function, blood eosinophil measurement, ACQ-6 scores, and diabetes

223 of this study were to determine whether the blood eosinophil molecular pattern of children with EoE

224 ficient mice exhibited diminished peripheral blood eosinophil numbers at baseline.

225 total immunoglobulin E levels and peripheral blood eosinophil numbers compared to A. fumigatus allerg

226 uding sex, age, body mass index, IgE levels, blood eosinophil numbers, Feno levels, and serum periost

227 led corticosteroid based therapy and who had blood eosinophils of 400 cells per muL or higher and one

228 ncontrolled eosinophilic asthma and baseline blood eosinophils of at least 300 cells per muL, possibl

229 dicators of TH2-like inflammation, including blood eosinophils (P = .001), exhaled nitric oxide (P =

230 n this study, we demonstrate that peripheral blood eosinophils (PBEos) can be successfully transfecte

231 for GM-CSF mRNA stabilization in peripheral blood eosinophils (pbeos).

232 d in vitro survival compared with peripheral blood eosinophils (PBEos).

233 atopy (IgE positive to >/= 1 allergen), and blood eosinophil percent (dichotomized at the median) we

234 We compared treatment efficacy according to blood eosinophil percentage (<2% and >/=2%, <3% and >/=3

235 d airway wall eosinophil counts (P = 0.003), blood eosinophil percentage (P = 0.03), bronchodilator r

236 age at recruitment, higher total IgE, higher blood eosinophil percentage and number, and higher treat

237 n of exhaled nitric oxide (Feno), peripheral blood eosinophil, periostin, YKL-40, and IgE levels and

238 ar patterns may partly explain the different blood eosinophil phenotypes in children vs adults with E

239 Forward scatter of blood eosinophils post-challenge was less heterogeneous

240 r 24 hours before incubation with peripheral blood eosinophils (purified with negative magnetic bead

241 muL, and >/=500 cells per muL) and baseline blood eosinophil ranges (<150 cells per muL, >/=150 cell

242 Blood eosinophil reactivity with monoclonal antibody (mA

243 l activation of beta1 and beta2 integrins on blood eosinophils, reported by monoclonal antibodies (mA

244 cell current rectification observed in human blood eosinophils resulted from the presence of an inwar

245 with elevated baseline levels of peripheral blood eosinophils, serum IgE, or periostin exhibited a g

246 ime to exacerbation outcomes on the basis of blood eosinophil subgroups of increasing cutoff levels.

247 st, 2% +/- 1% of freshly isolated peripheral blood eosinophils survived 5 days of culture without exo

248 In contrast, using a cutpoint of 2% for blood eosinophils, the risk of exacerbations was increas

249 reshold, recovery, exhaled nitric oxide, and blood eosinophils, there were 1.4 (95% confidence interv

250 combined with clinical judgement, a baseline blood eosinophil threshold of 150 cells/muL or greater o

251 of 150 cells/muL or greater or a historical blood eosinophil threshold of 300 cells/muL or greater w

252 cebo for patients with a combination of high blood eosinophil thresholds and a history of more freque

253 lizumab for patients with different baseline blood eosinophil thresholds and exacerbation histories.

254 rates were reduced increased with increasing blood eosinophil thresholds and with greater exacerbatio

255 , stratifying patients by different baseline blood eosinophil thresholds.

256 Investigate the usefulness of blood eosinophils to direct corticosteroid therapy durin

257 better biomarker than high concentrations of blood eosinophils to identify a patient subgroup with mo

258 In contrast to the transfer of untreated blood eosinophils to the lungs of recipient eosinophil d

259 mbrane currents were studied in single human blood eosinophils using the whole cell voltage clamp tec

260 Ras activation by FMLP in blood eosinophils was also enhanced following IL-5 primi

261 hibitory receptor CD300a in human peripheral blood eosinophils was investigated.

262 of cytokine production by normal peripheral blood eosinophils, we isolated eosinophils from healthy

263 analysis of mRNAs obtained from normal human blood eosinophils, we show in this report that the hemat

264 Human peripheral blood eosinophils were activated by SEB with or without

265 Isolated blood eosinophils were incubated on glass coverslips coa

266 Purified human peripheral blood eosinophils were incubated with IL-5 under various

267 Blood eosinophils were measured in the biomarker-directe

268 Peripheral blood eosinophils were obtained from volunteers with ast

269 Human peripheral blood eosinophils were treated with agonistic anti-Sigle

270 Human blood eosinophils were used to establish the impact of a

271 Peripheral blood eosinophils were used to study intracellular signa

272 (FEV1, fraction of exhaled nitric oxide, and blood eosinophils) were assessed over 12 weeks.

273 draining lymph nodes (LDLN), pretreatment of blood eosinophils with GM-CSF prior to transfer elicited

274 ging showed that treatment of EoL-1 cells or blood eosinophils with GM-CSF resulted in the reorganiza

275 Stimulation of AML14.3D10 cells or blood eosinophils with IL-5 induced rapid tyrosine phosp

276 lted in the near complete loss of peripheral blood eosinophils with no apparent impact on any other h

277 ere incubated with purified human peripheral blood eosinophils with or without activation in the pres

278 sinophils and GBM, we cultured human primary blood eosinophils with two separate human GBM-derived ce